3822 The Genomics and Personalized Medicine Act

In his inaugural speech President Obama stated, "We will restore science to itsrightful place and wield technologys wonders to raise health cares quality andlower its cost." As a junior senator from Illinois Mr. Obama introduced S.B.3822, "The Genomics and Personalized Medicine Act." The Acts goal is to"improve access to and appropriate utilization of valid, reliable, and accuratemolecular genetic tests by all populations, thus helping to secure the promiseof personalized medicine for all Americans." The new administrations vision is clear but without the proper technologies theroad is blocked. For the past ten years Simon Chin, Founder and CEO of IrisBioTechnologies, and his team have been developing the necessary tools to makethe Presidents vision of personalized medicine for all Americans a reality.These include the Iris BioWindows informatics system and Nano-Biochipgene-profiling platform, a powerful combination that enables the practice ofpersonalized medicine through the analysis of gene profiles and comprehensivelife dynamics. BioWindows is a HIPAA compliant, web based, medical information storage systemthat allows participants to grant selective or full sharing capabilities oftheir confidential medical and lifestyle information to physicians or familymembers anywhere in the world. This allows families to build multi-generationalmedical family trees that will help assure that they receive more personalizedcare now and in the future - the right medical treatment for the right patientat the right time. The other essential tool for personalized medicine is the ability to measure thebehavior of the many genes that are malfunctioning in any particular disease.The major diseases that inflict so much pain and suffering on our population arenot caused by the inheritance of faulty genes but by genes malfunctioning overtime due to lifestyle and other easily measured factors. The Iris Nano-Biochipplatform is designed to clinically measure each patients unique genomicprofile.

Combining these two tools, BioWindows and the Nano-Biochip, will offerphysicians a unique perspective concerning the relationship of a patients genesand their lifestyle dynamics, according to Mr Chin. Armed with this informationclinicians can truly personalize their medical treatments raising the quality ofour health care system and lowering its cost In 2008, The Dr. Wont it be nice when we can answer our 44th Presidents "yes we can"challenge with "yes we did" eradicate breast cancer. Last month, Iris BioTechnologies was selected, through a competitive screeningprocess, by the Biotechnology Industry Organization (BIO) to present at theEleventh Annual BIO CEO & Investor Conference in New York on February 9-10,2009.

"We are looking forward to presenting BioWindows 2.0 and our Nano-Biochiptechnology platform at this major investor conference," said Mr Chin, CEO ofIris BioTechnologies. Alan Eisenberg, executive vice president, Emerging Companies & BusinessDevelopment at BIO, said, "These leading companies represent the industrys mostpromising investment opportunities with late-stage clinical pipelines,well-established business strategies or strong M&A potential. Selected companiesare also distinguished by significant opportunities for value creation withnear-term clinical, regulatory and corporate catalysts that will help to supportour industry through the current economic downturn." When Frost and Sullivan bestowed Iris with their prestigious 2008 TechnologyInnovation Award in Pharmacogenomics, they said, "Iriss technology is anear-term opportunity, which would significantly transform the way in whichpersonalized medication is currently being prescribed." "It is very reassuring that both the Biotechnology Industry Organization (BIO)and Frost and Sullivan, using their own independent criteria and research, seethe same potential for Iris to grow and make a positive impact in the nearfuture," said Mr Chin. By categorizing individuals according to their genomicand personal profiles, Iris BioTechnologies accurately determines the optimalmedical solution for each patient through a proprietary informatics system,BioWindows. Iris's ever expanding database, in addition to their development ofthe Breast Cancer Chip, Comprehensive Cancer Chip, NeuroChip, CardioChip, andMetabolicChip adds to their extensive product pipeline.

Forward-Looking Statements The forward-looking statements contained herein are subject to certain risks anduncertainties that could cause actual results to differ materially from thosereflected in the forward-looking statements. Readers are cautioned not to placeundue reliance on these forward-looking statements, which reflect management'sanalysis only as of the date hereof. The company undertakes no obligation topublicly revise these forward-looking statements to reflect events orcircumstances that arise after the date thereof. Iris BioTechnologies Inc.Simon Chin, 408-867-2885President and Copyright Business Wire 2009.